We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Tranexamic Acid (topical, for melasma)
A topical brightening active applied to the skin for melasma and stubborn pigmentation — a cosmetic/derm active, not (in this context) ingested. Tranexamic acid (a drug best known as an antifibrinolytic) interrupts the plasmin signalling that activates melanocytes, reducing pigment. The honest framing: topical TXA performs comparably to hydroquinone in small split-face trials and is very well tolerated, but the strongest melasma evidence — a placebo-controlled RCT and favorable meta-analysis rankings — is for ORAL tranexamic acid, not topical, and topical efficacy is limited by skin penetration. A network meta-analysis ranks topical TXA below oral TXA, lasers, and triple-combination cream. These are cosmetic appearance outcomes, not health outcomes.
Topical cosmetic ingredient — not a dietary supplement
Tranexamic Acid (topical) is a topical cosmetic ingredient, not a supplement you take internally and not a drug. It is sold legally in skincare products to affect the appearance of skin (such as wrinkles). The evidence below comes mostly from small, often industry-funded studies of topical application, so treat the effect sizes cautiously. This page is for transparency and education, not a recommendation.
What the evidence says
Most Tranexamic Acid (topical) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2014–2026 with a typical study size of 50 participants.
Based on 992 studies · 376 meta-analyses · 552 RCTs · 50 total participants
Confidence
High confidenceBy outcome
9 more outcomes with fewer studies not shown.
A coherent plasmin-inhibition mechanism and multiple small split-face RCTs show topical TXA performs comparably to hydroquinone for melasma with excellent tolerability — but the strongest, placebo-controlled evidence is for ORAL TXA, network meta-analysis ranks topical TXA below oral/laser/triple-combination options, and topical penetration is a limit.
1,664 rigorous studies
1,063 randomized trials · 522 meta-analyses · 448 systematic reviews
Our evidence rating for Tranexamic Acid (topical) is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
19 trials ongoing or recruiting · 65 completed on ClinicalTrials.gov
16 of the completed trials have posted results
Registered trials show research momentum for Tranexamic Acid (topical), not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Tranexamic acid (TXA) is a synthetic lysine analogue best known as an antifibrinolytic medication; in dermatology it is used — orally, by injection, and topically — to treat melasma and stubborn hyperpigmentation.
This entry covers TOPICAL cosmetic/derm use (typically ~2-5% in serums); it is not about the ingested medication.
Mechanistically, TXA inhibits the plasminogen/plasmin pathway: by reducing plasmin in keratinocytes it dampens the UV-triggered signalling (arachidonic acid, prostaglandins, and melanocyte-stimulating factors) that activates melanocytes, and it can directly reduce melanin synthesis in melanoma cells, with an additive effect alongside arbutin in vitro.
The clinical evidence for topical TXA is genuine but modest and dominated by small split-face trials.
A double-blind split-face RCT (Ebrahimi & Naeini, 2014; 50 patients) found 3% topical TXA reduced MASI comparably to a 3% hydroquinone + 0.01% dexamethasone gold-standard, with significantly fewer side effects; a more recent split-face RCT in skin of color (Yasnova et al., 2024; 20 patients) similarly found 3% TXA cream as effective and safe as 4% hydroquinone.
The honest counterweights are decisive on where the strongest evidence sits: a route-comparison meta-analysis (Calacattawi et al., 2024; 22 RCTs, 1280 patients) found oral TXA produced the largest MASI reduction, ahead of injection and topical; and a network meta-analysis (Liu et al., 2021; 59 RCTs) ranked topical TXA below oral TXA, several lasers, triple-combination cream, and topical vitamin C, while also flagging a relatively high topical side-effect rate (~37%).
Topical penetration of this hydrophilic molecule is the recognised limit.
So the honest summary: topical TXA is a legitimate, well-tolerated, roughly hydroquinone-equivalent option for melasma in small trials, but it is not first-line and the oral route has better-quality support (oral TXA is a prescription use with its own clotting-risk considerations, separate from this topical entry).
None of this is a health claim. It is listed under Beauty & Appearance so it is discoverable, but is sandboxed out of ingestible-supplement stacks and the schedule optimizer; it carries a cosmetic badge and a topical-only disclaimer.
Tranexamic acid inhibits the plasminogen/plasmin system. In skin, less plasmin in keratinocytes means less UV-triggered release of the arachidonic-acid/prostaglandin and melanocyte-stimulating signals that drive pigment production — reducing melanocyte activation. It can also directly lower melanin synthesis in melanoma cells.
Melasma involves increased dermal vessels; TXA's antifibrinolytic/anti-angiogenic actions are proposed to reduce the vascular component of melasma, complementing its direct effect on pigment.
Topical use has limited data; discuss with a clinician. Do not take oral tranexamic acid for melasma in pregnancy without medical guidance.
This caution applies to ORAL/systemic tranexamic acid, not topical; never self-source oral TXA — it is a clinician decision.
Topical TXA is a gentle option; oral TXA, lasers, or triple-combination cream have stronger evidence — discuss with a dermatologist. Daily sunscreen is essential.
Generally layers well with niacinamide, vitamin C, and others; combining many actives can still irritate sensitive skin. This is a tolerability/formulation note, not a systemic drug interaction — topical use is not ingested. (Note: ORAL tranexamic acid does have systemic interactions/clotting considerations and is a separate prescription decision.)
Tip: Reduce frequency or concentration; patch-test on sensitive skin.
Tranexamic Acid (topical) has an evidence score of 6/10 — moderate evidence based on 1127 indexed studies, including 2 meta-analyses. A topical brightening active applied to the skin for melasma and stubborn pigmentation — a cosmetic/derm active, not (in this context) ingested. Tranexamic acid (a drug best known as an antifibrinolytic) interrupts the plasmin signalling that activates melanocytes, reducing pigment. The honest framing: topical TXA performs comparably to hydroquinone in small split-face trials and is very well tolerated, but the strongest melasma evidence — a placebo-controlled RCT and favorable meta-analysis rankings — is for ORAL tranexamic acid, not topical, and topical efficacy is limited by skin penetration. A network meta-analysis ranks topical TXA below oral TXA, lasers, and triple-combination cream. These are cosmetic appearance outcomes, not health outcomes. Representative study: PMID 34660626.
The commonly studied dose of Tranexamic Acid (topical) is Topical use, typically ~2-5% tranexamic acid in a serum applied to areas of melasma once or twice daily, alongside daily sunscreen. There is no oral or systemic dose in this cosmetic context — the ingested medication is a separate prescription use with clotting-risk considerations. This library does not provide an ingestion protocol.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Tranexamic Acid (topical) — consistent daily use matters more than the time of day. Topical tranexamic acid is a leave-on serum with no meal-timing relationship; consistent use plus daily sunscreen matters most for melasma.
Tranexamic Acid (topical) is generally well-tolerated and considered safe for most healthy adults at recommended doses. Reported side effects are uncommon and include mild local irritation or redness. Use caution if any of these apply to you: Topical use here is for skin only — do not self-medicate with oral tranexamic acid for melasma without a clinician (clotting-risk considerations); Known allergy or sensitivity to tranexamic acid or formulation excipients; Application to broken, irritated, or compromised skin until healed.
Sunscreen (SPF)
Mostly mechanism / observationalDaily broad-spectrum sunscreen — the single most evidence-based anti-aging skincare step there is, and the one most 'anti-aging' actives are really just trying to compensate for. The honest framing: this is the only topical on this list backed by a proper randomized controlled trial for skin aging itself. In the landmark Hughes 2013 trial (n=903), people randomized to daily sunscreen showed 24% less photoaging over 4.5 years — and no detectable increase in skin aging at all — while the mechanism (UV → matrix-metalloproteinase activation → collagen breakdown) is textbook. The same trial cohort also had less skin cancer. The honest caveats: the benefit is overwhelmingly prevention, not reversal of existing damage; real-world results depend entirely on applying enough and reapplying; and chemical (organic) UV filters are systemically absorbed above an FDA testing threshold (clinical significance unknown — mineral zinc-oxide/titanium-dioxide filters sidestep this). If you do one thing for your skin, it's this.
Tretinoin (Retin-A)
Mostly mechanism / observationalA prescription TOPICAL retinoid (Retin-A, Renova) — the acid form of vitamin A and the gold-standard, best-evidenced topical treatment for photoaging and acne. Multiple double-blind RCTs show it reduces fine wrinkles, mottled hyperpigmentation, and roughness over months, with histologic increases in dermal collagen. Caveats: retinoid dermatitis (irritation, peeling, dryness), photosensitivity, and it is CONTRAINDICATED IN PREGNANCY. Prescription drug, not a supplement; distinct from weaker OTC 'retinol' cosmetics.
Azelaic Acid
Mostly mechanism / observationalA topical skincare acid applied to the skin for rosacea, acne, and uneven tone — unusual among 'cosmetic' actives because it has genuine drug-grade evidence. Azelaic acid is a naturally occurring dicarboxylic acid that is anti-inflammatory, antimicrobial, and a tyrosinase inhibitor. It is sold both as an over-the-counter cosmetic (around 10%) AND as a 15-20% prescription medication. The honest framing: the strongest, best-replicated evidence — including double-blind phase III trials and a Cochrane review that rated it high-quality for papulopustular rosacea — used the PRESCRIPTION strengths (15-20%), not the ~10% OTC cosmetic form. It also has solid evidence for acne and melasma. Head-to-head it is beaten for acne (by benzoyl peroxide + clindamycin) and tends to cause more local irritation (burning, stinging) than several comparators. For rosacea or persistent acne, the prescription form under a clinician is the evidence-based route.
Hydroquinone
Mostly mechanism / observationalThe long-standing gold-standard topical skin-lightening agent for melasma and hyperpigmentation — and now a regulated drug, not a cosmetic. Hydroquinone (HQ) competitively inhibits tyrosinase and is toxic to overactive pigment cells. The honest framing: it is the most rigorously studied and most effective topical depigmenter — a large pivotal RCT, a Cochrane review, and recent meta-analyses all use HQ 4% (and the 'Kligman' triple-combination with a retinoid + steroid) as the benchmark that newer agents are measured against and rarely beat. But it carries real liabilities: irritation, rebound pigmentation, and — with prolonged or high-strength use — a disfiguring complication called exogenous ochronosis. For these reasons it was pulled from US over-the-counter sale in 2020 (now prescription-only) and is restricted in the EU and elsewhere. Effective, but for monitored, time-limited medical use.
Explore: Best supplements for Skin, Hair & Beauty
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 1,001 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.